Correction: Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein
Jing-Ren Tseng et al · SpringerOpen · 2026
Acceso al recurso
Entrá al contenido desde la opción principal o elegí otra fuente disponible.
Acceso abierto disponible
Cómo citar
Elegí el formato que necesitás y copiá la referencia al portapapeles.
APA 7
al, J. R. T. E. (2026). Correction: Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein. https://doi.org/10.1186/s13550-026-01443-7
MLA
al, Jing-Ren Tseng et. "Correction: Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein." 2026. https://doi.org/10.1186/s13550-026-01443-7.
Chicago
al, Jing-Ren Tseng et. 2026. "Correction: Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein.". https://doi.org/10.1186/s13550-026-01443-7.
Harvard
al, J. R. T. E. 2026, Correction: Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein, SpringerOpen, available at: https://doi.org/10.1186/s13550-026-01443-7 [Accessed 3 Jul. 2026].
Detalles del recurso
Información bibliográfica útil para confirmar que se trata del material correcto.
- Título
- Correction: Combined antitumor activity of [177Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein
- Autor / colaboradores
- Jing-Ren Tseng et al
- Editorial
- SpringerOpen
- Año de publicación
- 2026
- ISSN
- 2191-219X
- ISSN
- 2191-219X
- Idioma
- eng